Gocovri Now Available to Treat Dyskinesia in Parkinson's Disease Patients

Gocovri is available as extended-release capsules for oral administration
Gocovri is available as extended-release capsules for oral administration

Adamas announced the availability of Gocovri (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. 

Gocovri was approved by the Food and Drug Administration (FDA) in August 2017 as the first drug for this indication. The exact mechanism by which Gocovri exerts its effects in the treatment of dyskinesia in Parkinson's disease patients is unknown. 

Related Articles

If needed, Gocovri capsules may be administered by opening and sprinkling the entire contents on a teaspoonful of soft food (eg, applesauce). Treatment with Gocovri is contraindicated in patients with end stage renal disease (creatinine clearance <15mL/min/1.73m2). 

Gocovri is available as 68.5mg and 137mg strength extended-release capsules in 60-count bottles.

For more information call (844) 462-6874 or visit Gocovri.com.